Navigation Links
Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
Date:9/26/2011

in this patient population, in addition to providing superior functional and cosmetic outcomes for those patients with recurrent or otherwise complicated and difficult to treat skin cancers.  This simple and novel delivery of bleomycin, an approved chemotherapeutic agent, through reversible electroporation has shown a marked improvement in potency, while delivering a much lower and safer concentration of the drug."

"With positive results from these multiple clinical studies, OMS ElectroChemotherapy™ demonstrates clinical benefit for patients with manageable side effects," said, Punit Dhillon, president and CEO. "We strongly believe in the clinical relevance of our therapeutic approach and believe these results demonstrate tolerability, efficacy and point to the combinability of this novel treatment approach with current available therapies for the management of local tumors.  Clinical experience from these programs supports the uniqueness of OMS ElectroChemotherapy™ in its ability to achieve selective destruction of cancerous tumors while sparing healthy normal tissue including highly vascularized and innervated surrounding structures, providing physicians with an important flexible treatment alternative."

About OncoSec Medical Inc.

OncoSec Medical (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy™. More information is available at '/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. UPDATE: Total Victory for Schering-Plough (Now Merck) Pharmaceutical Reps in National Suit for Overtime Pay
2. UPDATE: FDA Approves New Drug to Treat Chronic Obstructive Pulmonary Disease
3. Update: Clinical Trial Establishes Catheter-based Aortic Valve Replacement As New Standard of Care for Patients Who Cannot Undergo Surgery
4. UPDATE: China PharmaHub Corp. Introduces a Magic Bullet Liver Cancer Therapy to China, Hong Kong, Taiwan, Macau, Singapore, Malaysia, and Bangladesh
5. Update: International HIV/AIDS Partnership Wins Two Awards for Supply Chain Excellence
6. UPDATE: FDA Issues 22 Warning Letters to Web site Operators
7. UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPars Investigational Cancer Drug BSI-201
8. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
9. UPDATE: Infant Primates Given Vaccines on U.S. Childrens Immunization Schedule Develop Behavioral Symptoms of Autism
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. UPDATE: New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... SALT LAKE CITY , June 18, 2013 ... registry-based informatics products for healthcare and life sciences ... U.S. General Services Administration (GSA) IT Schedule 70 ... is now certified to provide innovative IT solutions ... levels. In accordance with this contract, Remedy has ...
(Date:6/18/2013)... --  Polymer Technology Systems, Inc. (PTS) announced ... to integrate the CardioChek ® PA system ... systems across the country. The CardioChek PA lipid ... Hanson Medical Systems , offers immediate, on-site ... triglycerides, and glucose. (Logo: http://photos.prnewswire.com/prnh/20130618/DE33611LOGO ...
(Date:6/17/2013)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... preliminary prospectus supplement to its effective shelf registration statement on ... securities regulatory authorities in each of the provinces of ... of its common shares to raise gross proceeds of approximately ... grant to the underwriters of the Offering an option, exercisable ...
Breaking Medicine Technology:Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 2Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 3Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 4Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4
(Date:6/18/2013)... (PRWEB) June 18, 2013 The ... battery powered, stand-alone device which can be used to ... stainless steel enclosure of the Temp1000IS comes with the ... with the IFC400 (sold separately) docking station ... for full communications. No more removal of end-caps to ...
(Date:6/18/2013)... 2013 Biomet hip lawsuit ... forward in a multidistrict litigation in U.S. District Court, ... According to court records, the litigation’s most recent status ... the Court also convened a motions hearing and a ... the Biomet hip replacement litigation. The proceeding’s next ...
(Date:6/18/2013)... Hospitals Case Medical Center clinical researchers have launched ... which will evaluate the ability of a patient,s ... end stage peripheral arterial disease (PAD). , ... Surgery at University Hospitals Case Medical Center,s Harrington ... at Case Western Reserve University School of Medicine, ...
(Date:6/18/2013)... June 18, 2013 The Elizabeth Glaser ... State and the U.S. President’s Emergency Plan for AIDS ... celebrate significant new milestones in the global effort to ... Kerry announced that as of June 2013, one million ... support. Since PEPFAR’s inception in 2003, EGPAF has ...
(Date:6/18/2013)... UT (PRWEB) June 18, 2013 Today, ... Health Reimbursement Accounts . Zane Benefits, which provides ... benefits, is the leader in defined contribution ... to Zane Benefits’ website, employees of a company who ... may have questions about how Health Reimbursement Accounts work. ...
Breaking Medicine News(10 mins):Health News:MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3Health News:Zane Benefits Publishes New Information on Health Reimbursement Accounts 2
... ... one-stop, flat-fee healthcare information technology and support, announced it is bringing ... the hiring of new Chief Healthcare Officer Joel Taylor. Taylor joins ... to practices and medical groups of all scopes and sizes, with ...
... Tuesday, October 13, in response to national calls for an ... announce their "patient-centered" plan for health care reform. The ... policy specialist Art Laffer, will be described in detail, together ... to the press (dial-in information is below). , ...
... ... for Cell Sense in vivo imaging agent , ... Pittsburgh, PA (Vocus) October 12, 2009 -- Celsense, Inc. announced today ... imaging reagent, Cell Sense CS-1000 (Cell Sense). , ,Celsense filed a Drug Master File (a “DMF”) ...
... ... help to otherwise untreatable symptoms of Multiple Sclerosis. , ... Camillo, CA (PRWEB) October 12, 2009 -- , , , ,The ... country a sometimes first in years relief from the relentless progressive symptoms of the disease. ...
... is forming the world,s first national centre for research into ... Arthritis Research Campaign and The University of Nottingham, it will ... cause of chronic pain which affects more than ten ... awarded funding of 2.5m over five years and the University ...
... Oct. 11 Canary Foundation, a nonprofit organization that ... its founder and chairman, Don Listwin, has been elected ... (BSA). Members are appointed to 5-year terms by the ... advice on science program policy, programs and initiatives to ...
Cached Medicine News:Health News:ITelagen Taps Joel Taylor as Chief Healthcare Officer New Executive to Spearhead EMR Implementations 2Health News:ITelagen Taps Joel Taylor as Chief Healthcare Officer New Executive to Spearhead EMR Implementations 3Health News:The Obamacare Alternative: 33 State Think Tanks Announce Patient-Centered Health Care Reforms 2Health News:Celsense, Inc Files FDA & EMEA Regulatory Submissions 2Health News:Celsense, Inc Files FDA & EMEA Regulatory Submissions 3Health News:People with Multiple Sclerosis are Proactively Improving their Walking, Energy Level, Confidence and Quality of Life 2Health News:People with Multiple Sclerosis are Proactively Improving their Walking, Energy Level, Confidence and Quality of Life 3Health News:National pain research center will bring hope to millions 2Health News:National pain research center will bring hope to millions 3Health News:National pain research center will bring hope to millions 4Health News:Canary Foundation's Don Listwin Appointed to National Cancer Institute's Board of Scientific Advisors 2
... High performance fiberoptic imaging from ... ,Olympus has improved its fiberscope range, ... specifications and enhanced image performance. Olympus ... instruments for diagnosis and therapy in ...
... been designed with a large 2.8mm instrument ... This permits the selection of a wide ... procedures. In addition, this model features excellent ... and a bright, high-resolution image. It also ...
Indications For Usage: , Thoracic surgery. , Broncho-spirometry. , Thoracoscopies. , Differential or selective lung ventilation. ...
... Silbroncho is a double lumen tube made of ... tip., ,Due to the characteristics of silicone ... the patient at insertion. Furthermore, the tube will ... suitable for long term surgery., ,Silbronco is ...
Medicine Products: